ReviewFrontiers in oncology2021

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors.

Farbod Shojaei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.